Penny Stock Signal: ATXI
Report Date: 01-08-2024
Symbol: ATXI - Avenue Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Penny Stock Signal: ATXI
Avenue Therapeutics, Inc. (ATXI)
2 Gansevoort St Fl 9
New York City, NEW YORK 10014
Phone: 17816524500
Website: http://www.avenuetx.com
CEO: Dr. Lucy Lu
NASDAQ, Nasdaq Capital Market
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York. Effective as of December 31, 2019, Avenue Therapeutics, Inc. operates as a subsidiary of InvaGen Pharmaceuticals, Inc.